Skip to main content
SpringerLink
Log in

The Anabolic Androgenic Steroid Oxandrolone in the Treatment of Wasting and Catabolic Disorders

Review of Efficacy and Safety

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

There has been increasing interest in the development of effective agents that can be safely used to promote anabolism in the clinical setting for patients with chronic wasting conditions as well as in the prevention and treatment of frailty associated with loss of muscle tissue in aging (sarcopenia).

One such agent is the anabolic androgenic steroid (AAS) oxandrolone, which has been used in such clinical situations as HIV-related muscle wasting, severe burn injury, trauma following major surgery, neuromuscular disorders and alcoholic hepatitis for over 30 years. In the US, oxandrolone is the only AAS that is US FDA-approved for restitution of weight loss after severe trauma, major surgery or infections, malnutrition due to alcoholic cirrhosis, and Duchenne’s or Becker’s muscular dystrophy.

Our review of the use of oxandrolone in the treatment of catabolic disorders, HIV and AIDS-related wasting, neuromuscular and other disorders provides strong evidence of its clinical efficacy. Improvements in body composition, muscle strength and function, status of underlying disease or recovery from acute catabolic injury and nutritional status are significant in the vast majority of well designed trials. However, oxandrolone has not yet been studied in sarcopenia.

Unlike other orally administered C17α-alkylated AASs, the novel chemical configuration of oxandrolone confers a resistance to liver metabolism as well as marked anabolic activity. In addition, oxandrolone appears not to exhibit the serious hepatotoxic effects (jaundice, cholestatic hepatitis, peliosis hepatis, hyperplasias and neoplasms) attributed to the C17α-alkylated AASs. Oxandrolone is reported to be generally well tolerated and the most commonly documented adverse effects are transient elevations in transaminase levels and reductions in high density lipoprotein cholesterol level.

However, optimal risk: benefit ratios for oxandrolone and other agents in its class will need to be refined before widespread clinical acceptance of AASs as a therapeutic option in sarcopenia and other chronic wasting conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Basaria S, Wahlstrom JT, Dobs AS. Anabolic-androgenic steroid therapy in the treatment of chronic disease. J Clin Endocrinol Metab 2001; 86(11): 5108–17

    Article  PubMed  CAS  Google Scholar 

  2. Kuhn CM. Anabolic steroids. Recent Prog Horm Res 2002; 57: 411–34

    Article  PubMed  CAS  Google Scholar 

  3. Sheffield-Moore M, Urban R, Wolf SE, et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 1999; 84(8): 2705–11

    Article  PubMed  CAS  Google Scholar 

  4. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3469–75

    Article  PubMed  CAS  Google Scholar 

  5. Hasten DL, Pak-Loduca J, Obert KA, et al. Resistance exercise acutely increases MHC and mixed muscle protein synthesis rates in 78–84 and 23–32 yr olds. Am J Physiol Endocrinol Metab 2000; 278(4): E620–6

    PubMed  CAS  Google Scholar 

  6. Ferrando AA, Sheffield-Moore M, Wolf SE, et al. Testosterone administration in sever burns ameliorates muscle catabolism. Crit Care Med 2001; 29(10): 1936–42

    Article  PubMed  CAS  Google Scholar 

  7. Urban R, Bodenburgh Y, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: E820–6

    PubMed  CAS  Google Scholar 

  8. Kutscher EC, Lund BC, Perry PJ. Anabolic steroids a review for the clinician. Sports Med 2002; 32(5): 285–96

    Article  PubMed  Google Scholar 

  9. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335(1): 1–7

    Article  PubMed  CAS  Google Scholar 

  10. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003; 51(1): 101–15

    Article  PubMed  Google Scholar 

  11. Fox M, Minot AS, Liddle GW. Oxandrolone: a potent anabolic steroid of novel chemical configuration. J Clin Endocrinol Metab 1962; 22: 921–4

    Article  PubMed  CAS  Google Scholar 

  12. Gerondache CN, Dowling WJ, Pincus G. Metabolic changes induced in elderly patients with an anabolic steroid (oxandrolone). J Gerontol 1967; 22(3): 290–300

    Article  Google Scholar 

  13. Karim A, Ranney R, Zagarella J, et al. Oxandrolone disposition and metabolism in man. Clin Pharmacol Ther 1973; 14(5): 862–9

    PubMed  CAS  Google Scholar 

  14. Harrison L, Martin D, Gotlin R, et al. Effect of extended use of single anabolic steroids on urinary steroid excretion and metabolism. J Chromatogr 1989; 489(1): 121–6

    Article  PubMed  CAS  Google Scholar 

  15. Bi H, Masse R. Studies on anabolic steroids. 12: epimerization and degradation of anabolic 17 beta-sulfate-17 alpha-methyl steroids in human: qualitative and quantitative CG/MS analysis. J Steroid Biochem Mol Biol 1992; 42(5): 533–46

    CAS  Google Scholar 

  16. Albanese A, Lorenze E, Orto L. Nutritional and metabolic effects of some newer steroids. N Y State J Med 1962; 62: 1607–16

    PubMed  CAS  Google Scholar 

  17. Link K, Blizzard R, Evans W, et al. The effect of androgens on the pulsatile release and the twenty-four hour mean concentration of growth hormone in peripubertal males. J Clin Endocrinol Metab 1986; 62(1): 159–64

    Article  PubMed  CAS  Google Scholar 

  18. Lennon D, Saunders F. Anabolic activity of 2-oxa-17-alpha methyldihydrotestosterone (oxandrolone) in castrated rats. Steroids 1964; 4: 689–97

    Article  CAS  Google Scholar 

  19. Jackson S, Rallison M, Buntin W, et al. Use of oxandrolone for growth stimulation in children. Am J Dis Child 1973; 126: 481–4

    PubMed  CAS  Google Scholar 

  20. Mendenhall CL, Moritz TE, Roselle GA, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group # 275. JPEN J Parenter Enteral Nutr 1995; 19(4): 258–65

    Article  PubMed  CAS  Google Scholar 

  21. Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17(4): 564–76

    Article  PubMed  CAS  Google Scholar 

  22. Bonkovsky HL, Fiellin DA, Slaker DP, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I: short-term effects on liver function. Am J Gastroenterol 1991; 86(9): 1200–8

    CAS  Google Scholar 

  23. Bonkovsky HL, Singh RH, Jafri IH, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II: short-term effects on nitrogen metabolism, metabolic balance, and nutrition. Am J Gastroenterol 1991; 86(9): 1209–18

    CAS  Google Scholar 

  24. Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311(23): 1464–70

    Article  PubMed  CAS  Google Scholar 

  25. Demling R, DeSanti L. The anabolic steroid, oxandrolone, reverses the wound healing impairment in corticosteroid-dependent burn and wound patients. Wounds 2001; 13(5): 203–8

    Google Scholar 

  26. Demling R, DeSanti L. The rate of restoration of body weight after burn injury, using the anabolic agent oxandrolone, is not age dependent. Burns 2001; 27(1): 46–51

    Article  PubMed  CAS  Google Scholar 

  27. Demling R, Orgill D. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care 2000; 15(1): 12–7

    Article  PubMed  CAS  Google Scholar 

  28. Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. Ann Surg 2001; 233(4): 556–64

    Article  PubMed  CAS  Google Scholar 

  29. Morton R, Gleason O, Yates W. Psychiatric effects of anabolic steroids after burn injuries. Psychosomatics 2000; 41(1): 66–8

    Article  PubMed  CAS  Google Scholar 

  30. Demling R. Comparison of the anabolic effects and complications of human growth hormone and the testosterone analog, oxandrolone, after severe burn injury. Burns 1999; 25(3): 215–21

    Article  PubMed  CAS  Google Scholar 

  31. Demling RH, DeSanti L. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma 1997; 43(1): 47–51

    Article  PubMed  CAS  Google Scholar 

  32. Aleem RF, Walaszek PS, Gamelli RL. Effect of oxandrolone on outcome in patients with thermal injury [abstract]. J Burn Care Rehabil 1999; 20(1): S199

    Google Scholar 

  33. Demling RH, DeSanti L. The beneficial effects of the anabolic steroid oxandrolone in the geriatric burn population. Wounds 2003; 15(2): 54–8

    Google Scholar 

  34. Gervascio JM, Dickerson RN, Swearingen J, et al. Oxandrolone in trauma patients. Pharmacotherapy 2000; 20(11): 1328–34

    Article  Google Scholar 

  35. Yeh S, DeGuzman B, Kramer T. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 2002; 122(2): 421–8

    Article  PubMed  CAS  Google Scholar 

  36. Bowen RE, Dutko L, Christman S. The effects of oxandrolone on performance in patients with COPD [abstract]. Chest 1998; 114 Suppl. 4: 318S

    Article  Google Scholar 

  37. Kravetz JD, Lee C, Dietrich DT. Oxandrolone use in Crohn’s disease. Am J Gastroenterol 1997; 92(12): 2230–1

    Google Scholar 

  38. Cioroiu M, Hanan SH. Adjuvant anabolic agents: a case report on the successful use of oxandrolone in an HIV-positive patient with chronic stasis ulceration. J Wound Ostomy Continence Nurs 2001; 28(4): 215–8

    PubMed  CAS  Google Scholar 

  39. Earthman CP, Reid PM, Harper IT, et al. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. JPEN J Parenter Enteral Nutr 2002; 26(6): 357–65

    Article  PubMed  Google Scholar 

  40. Fox-Wheeler S, Heller L, Salata C, et al. Evaluation of the effects of oxandrolone in malnourished HIV-positive pediatric patients. Pediatrics 1999; 104(6): E731–7

    Article  Google Scholar 

  41. Romeyn N, Gunn N. Resistance exercise and oxandrolone for men with HIV-related weight loss. JAMA 2000; 284(2): 176–7

    Article  PubMed  CAS  Google Scholar 

  42. Strawford A, Barbieri T, Loan MV, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. JAMA 1999; 281(14): 1282–90

    Article  PubMed  CAS  Google Scholar 

  43. Fisher A, Abbaticola M, The Oxandrolone Study Group. The effects of oxandrolone on the body composition in patients with HIV-associated weight loss [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–15; Chicago

  44. Pharo A, Salvato P, Vergel N, et al. Oxandrolone: anabolic steroid use in HIV positive women [abstract]. Nutrition 1997; 13(3): 268

    Article  Google Scholar 

  45. Poles M, Meller J, Lin A, et al. Oxandrolone as a treatment for HIV-associated weight loss: a one year follow up [abstract]. Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto

  46. Salvato P, Thompson C, Vergel N, et al. Anabolic steroid use in HIV/AIDS patients [abstract]. Nutrition 1997; 13(3): 268

    Article  Google Scholar 

  47. Fisher A, Abbaticola M. Effects of oxandrolone and l-glutamine on body weight, body cell mass, and body fat in patients with HIV infection: preliminary analysis [abstract]. Nutrition 1997; 13(3): 279

    Article  Google Scholar 

  48. Berger JR, Pall L, Hall CD, et al. Oxandrolone in AIDS-wasting myopathy. AIDS 1996; 10: 1657–62

    Article  PubMed  CAS  Google Scholar 

  49. Fenichel GM, Griggs RC, Kissel J, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001; 56(8): 1075–9

    Article  PubMed  CAS  Google Scholar 

  50. Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58: 1081–7

    Article  PubMed  CAS  Google Scholar 

  51. Rosenfeld J, King RM, Smith JE. Oxandrolone in ALS: preliminary analysis. Amyotroph Lateral Schier Other Motor Neuron Disord 2000; 1 Suppl. 4: 21–5

    Google Scholar 

  52. Fenichel G, Pestronk A, Florence J, et al. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology 1997; 45(5): 1225–6

    Article  Google Scholar 

  53. Spungen AM, Koehler KM, Modeste-Duncan R, et al. 9 clinical cases of nonhealing pressure ulcers in patients with spinal cord injury treated with an anabolic agent: a therapeutic trial. Adv Skin Wound Care 2001 May/Jun; 14(3): 139–44

    Article  PubMed  CAS  Google Scholar 

  54. Spungen AM, Grimm DR, Strakhan M, et al. Treatment with an anabolic agent is associated with improvement in respiratory function in persons with tetraplegia: a pilot study. Mt Sinai J Med 1999; 66(3): 201–5

    PubMed  CAS  Google Scholar 

  55. Demling R, DeSanti L. Closure of the ‘non-healing’ wound corresponds with correction of weight loss using the anabolic agent oxandrolone. Ostomy Wound Manage 1998; 44(10): 58–62, 64, 66 passim

    PubMed  CAS  Google Scholar 

  56. Barakat AJ, Castaldo AJ. Successful use of oxandrolone in the prophylaxis of hereditary angioedema: a case report. Pediatr Asthma Allergy Immunol 1999; 13(4): 189–93

    Article  Google Scholar 

  57. Lovejoy J, Bray G, Greeson C, et al. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int J Obes Relat Metab Disord 1995; 19(9): 614–24

    PubMed  CAS  Google Scholar 

  58. Malmendier CL, van den Bergen CJ, Emplit G, et al. A long-term study of the efficacy of oxandrolone in hyperlipoproteinemias. J Clin Pharmacol 1978; 18(1): 42–53

    PubMed  CAS  Google Scholar 

  59. Enholm C, Huttunen JK, Kinnunen PJ, et al. Effect of oxandrolone treatment on the activity of lipoprotein lipase, hepatic lipase and phospholipase al of human postheparin plasma. N Engl J Med 1975; 292: 1314–7

    Article  Google Scholar 

  60. Doyle A, Pinkus N, Green J. The use of oxandrolone in hyperlipidaemia. Med J Aust 1974; 1: 127–9

    PubMed  CAS  Google Scholar 

  61. Segal S, Cooper J, Bolognia J. Treatment of lipodermatosclerosis with oxandrolone in a patient with stanozolol-induced hepatotoxicity. J Am Acad Dermatol 2000; 43(3): 558–9

    Article  PubMed  CAS  Google Scholar 

  62. Sansoy OM, Roy AN, Shields LM. Anabolic action and side effects of oxandrolone in 34 mental patients. Geriatrics 1971; 26: 139–43

    PubMed  CAS  Google Scholar 

  63. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984; 12(6): 469–83

    Article  PubMed  CAS  Google Scholar 

  64. Graham S, Kennedy M. Recent developments in the toxicity of anabolic steroids. Drug Saf 1990; 5(6): 458–76

    Article  PubMed  CAS  Google Scholar 

  65. Stone MH. Literature review: anabolic-androgenic steroid use by athletes. Nat Strength Condit Assoc J 1993; 15(2): 10–28

    Article  Google Scholar 

  66. Bahrke MS, Yesalis CE, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. Sports Med 1996; 22(6): 367–90

    Article  PubMed  CAS  Google Scholar 

  67. Yesalis CE. Anabolic steroids in sport and exercise. Champaign (IL): Human Kinetics, 2000

  68. Parssinen M, Seppala T. Steroid use and long-term health risks in former athletes. Sports Med 2002; 32(2): 83–94

    Article  PubMed  Google Scholar 

  69. Winwood P, Robertson D, Wright R. Bleeding oesophageal varices associated with anabolic steroid use in an athlete. Postgrad Med J 1990; 66: 864–5

    Article  PubMed  CAS  Google Scholar 

  70. Maddrey W. Is therapy with testosterone or anabolic-androgenic steroids useful in the treatment of alcoholic liver disease? Hepatology 1986; 6: 1033–5

    Article  PubMed  CAS  Google Scholar 

  71. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/ androgenic steroids. Semin Liver Dis 1987; 7(3): 230–6

    Article  PubMed  CAS  Google Scholar 

  72. Kelley V, Ruvalcaba R. Use of anabolic agents in the treatment of short children. Clin Endocrinol Metab 1982; 11: 25–39

    Article  PubMed  CAS  Google Scholar 

  73. Friedl KE. Effects of anabolic steroids on physical health. In: Yesalis CE, editor. Anabolic steroids in sport and exercise. 2nd ed. Champaign (IL): Human Kinetics, 2000: 175–223

    Google Scholar 

  74. Zimmerman HJ, Ishak KG. Steroids and other hormones. In: Cameron RG, Feuer G, de la Iglesia FA, editors. Drug-induced hepatotoxicity. Berlin: Springer-Verlag, 1996: 543–79

    Chapter  Google Scholar 

  75. Wilson J, Griffin J. The use and abuse of androgens. Metabolism 1980; 29: 1278–90

    Article  PubMed  CAS  Google Scholar 

  76. Raiti S, Trias E, Levitsky L, et al. Oxandrolone and human growth hormone: comparison of growth-stimulating effects in short children. Am J Dis Child 1973; 126: 597–600

    PubMed  CAS  Google Scholar 

  77. Danowski TS, Lee FA, Cohn RE, et al. Oxandrolone therapy of growth retardation. Am J Dis Child 1965; 109: 526–32

    PubMed  CAS  Google Scholar 

  78. Naeraa R, Nielsen J, Pedersen I, et al. Effect of oxandrolone on growth and final height in Turner’s syndrome. Acta Pediatr Scand 1990; 79: 784–9

    Article  CAS  Google Scholar 

  79. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001; 23(9): 1355–89

    Article  PubMed  CAS  Google Scholar 

  80. Dickerman RD, Pertusi RM, Zachariah NY, et al. Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med 1999; 9: 34–9

    Article  PubMed  CAS  Google Scholar 

  81. Slater S, Davidson J, Patrick R. Jaundice induced by stanozolol hypersensitivity. Postgrad Med J 1976; 52(606): 229–32

    Article  PubMed  CAS  Google Scholar 

  82. Holder L, Gnarra D, Lampkin B, et al. Hepatoma associated with anabolic steroid therapy. Am J Roentgenol Radium Ther Nucl Med 1975; 124: 638–42

    PubMed  CAS  Google Scholar 

  83. Boue F, Coffin B, Delfraissy J. Danazol and cholestatic hepatitis. Ann Intern Med 1986; 105(1): 139–40

    PubMed  CAS  Google Scholar 

  84. Bray G, Tredger J, Williams R. Resolution of danazol-induced cholestasis with s-adenosylmethionine. Postgrad Med J 1993; 69(809): 237–9

    Article  PubMed  CAS  Google Scholar 

  85. Ohsawa T, Iwashita S. Hepatitis associated with danazol. Drug Intell Clin Pharm 1986; 20: 889

    PubMed  CAS  Google Scholar 

  86. Borhan-Manesh F, Farnum JB. Methyltestosterone-induced cholestasis: the importance of disproportionately low serum alkaline phosphatase level. Arch Intern Med 1989; 124: 2127–9

    Article  Google Scholar 

  87. Evely R, Triger D, Milnes J, et al. Severe cholestasis associated with stanozolol. BMJ 1987; 294: 612–3

    Article  PubMed  CAS  Google Scholar 

  88. Goldenberg I. Hormonal therapy of women for metastatic carcinoma. Cancer Chemother 1965; 44: 49–51

    CAS  Google Scholar 

  89. Paradinas F, Bull T, Westaby D, et al. Hyperplasia and prolapse of hepatocytes into hepatic veins during long term methyltestosterone therapy: possible relationships of these changes to the development of peliosis hepatis and liver tumors. Histopathology 1977; 1: 225–6

    Article  PubMed  CAS  Google Scholar 

  90. Bagheri S, Boyer J. Peliosis hepatis associated with androgenic-anabolic steroid therapy: a severe form of hepatic injury. Ann Intern Med 1974; 81: 610–8

    PubMed  CAS  Google Scholar 

  91. Kintzen W, Silny J. Peliosis hepatis after administration of fluoxymesterone. CMAJ 1960; 83: 860–2

    CAS  Google Scholar 

  92. Groos G, Arnold O, Brittinger G. Peliosis hepatis after long-term administration of oxymetholone [letter]. Lancet 1974; I(7826): 874

    Article  Google Scholar 

  93. McDonald EC, Speicher CE. Peliosis hepatis associated with administration of oxymetholone. JAMA 1978; 240(3): 243–4

    Article  PubMed  CAS  Google Scholar 

  94. Bernstein M, Hunter R, Yachnin S. Hepatoma and peliosis hepatis developing in a patient with Fanconi’s anemia. N Engl J Med 1971; 284(20): 1135–6

    Article  PubMed  CAS  Google Scholar 

  95. Arnold G, Kaplan M. Peliosis hepatis due to oxymetholone: a clinically benign disorder. Am J Gastroenterol 1979; 71: 213–6

    PubMed  CAS  Google Scholar 

  96. Makdisi W, Cherian R, Vanveldhuizen P, et al. Fatal peliosis of the liver and spleen in a patient with agnogenic myeloid metaplasia treated with danazol. Am J Gastroenterol 1995; 90(2): 317–8

    PubMed  CAS  Google Scholar 

  97. Cabasso A. Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc 1994; 26: 2–4

    PubMed  CAS  Google Scholar 

  98. Westaby D, Ogle S, Paradinas F, et al. Liver damage from long-term methyltestosterone. Lancet 1977; II(8032): 261–3

    Article  Google Scholar 

  99. Alberti-Flor J, Iskandarani M, Jeffers L, et al. Focal nodular hyperplasia associated with the use of a synthetic anabolic androgen. Am J Gastroenterol 1984; 79(2): 150–1

    PubMed  CAS  Google Scholar 

  100. Fermand J, Levy Y, Bouscary D, et al. Danazol-induced hepatocellular adenoma. Am J Med 1990; 88(5): 529–30

    Article  PubMed  CAS  Google Scholar 

  101. Bork K, Pitton M, Harten P, et al. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999; 353: 1066–7

    Article  PubMed  CAS  Google Scholar 

  102. Anthony P. Hepatoma associated with androgenic steroids. Lancet 1975; I(7908): 685–6

    Article  Google Scholar 

  103. Bruguera M. Hepatoma associated with androgenic steroids [letter]. Lancet 1975; I: 1295

    Google Scholar 

  104. Hernandez-Nieto L, Bruguera M, Bombi J, et al. Benign liver-cell adenoma associated with long-term administration of androgenic-anabolic steroid (methandienone). Cancer 1977; 40(4): 1761–4

    Article  PubMed  CAS  Google Scholar 

  105. Overly W, Dankoff J, Wang B, et al. Androgens and hepatocellular carcinoma in an athlete. Ann Intern Med 1984; 100(1): 158–9

    PubMed  CAS  Google Scholar 

  106. Creagh T, Rubin A, Evans D. Hepatic tumours induced by anabolic steroids in an athlete. J Clin Pathol 1988; 41(4): 441–3

    Article  PubMed  CAS  Google Scholar 

  107. Goldman B. Liver carcinoma in an athlete taking anabolic steroids [letter]. J Am Osteopath Assoc 1985; 85: 56

    PubMed  CAS  Google Scholar 

  108. Edis AL, Levitt M. Anabolic steroids and colon cancer. Med J Aust 1985; 142: 426–7

    PubMed  CAS  Google Scholar 

  109. Johnson FL, Feagler JR, Lerner KG, et al. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972; II(7790): 1273–6

    Article  Google Scholar 

  110. Henderson JT, Richmond J, Sumerling MD. Androgenic-anabolic steroid therapy and hepatocellular carcinoma [letter]. Lancet 1973; I(7809): 934

    Article  Google Scholar 

  111. Farrell G, Joshua D, Uren R, et al. Androgen-induced hepatoma. Lancet 1975; I(7904): 430–1

    Article  Google Scholar 

  112. Lesna M, Spencer I, Walker W. Liver nodules and androgens [letter]. Lancet 1976; I(7969): 1124

    Article  Google Scholar 

  113. Mokrohisky ST, Ambruso DR, Hathaway WE. Fulminant hepatic neoplasia after androgen therapy. N Engl J Med 1977; 296(24): 1411–2

    Article  PubMed  CAS  Google Scholar 

  114. Shapiro P, Ikeda R, Ruebner B, et al. Multiple hepatic tumours and peliosis hepatis in Fanconi’s anemia treated with androgens. Am J Dis Child 1977; 131: 1104–6

    PubMed  CAS  Google Scholar 

  115. Carrasco D, Prieto M, Pallardo L, et al. Multiple hepatic adenomas after long-term therapy with testosterone enanthate: review of the literature. J Hepatol 1985; 1: 573–8

    Article  PubMed  CAS  Google Scholar 

  116. Griffin JE, Ojeda SR. Textbook of endocrine physiology. 4th ed. New York: Oxford University Press, 2000

    Google Scholar 

  117. Rosenberg IH. Summary comments. Am J Clin Nutr 1989; 50: 1231–3

    Google Scholar 

  118. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 2000; 55A(12): M716–24

    Article  CAS  Google Scholar 

  119. Roubenoff R, Heymsfield SB, Kehayias JJ, et al. Standardization of nomenclature of body composition in weight loss. Am J Clin Nutr 1997; 66: 192–6

    PubMed  CAS  Google Scholar 

  120. Zoico E, Roubenoff R. The role of cytokines in regulating protein metabolism and muscle function. Nutr Rev 2002; 60(2): 39–51

    Article  PubMed  Google Scholar 

  121. Richelson L, Wahner H, Melton L, et al. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984; 311(20): 1273–5

    Article  PubMed  CAS  Google Scholar 

  122. Davidson B, Ross R, Paganini-Hill A, et al. Total and free estrogens and androgens in post-menopausal women with hip fractures. J Clin Endocrinol Metab 1982; 54: 115-20

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. School of Exercise and Sport Science, Faculty of Health Sciences, The University of Sydney, Sydney, Australia

    Rhonda Orr & Maria Fiatarone Singh

  2. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, USA

    Maria Fiatarone Singh

  3. Hebrew Rehabilitation Center for Aged, Boston, Massachusetts, USA

    Maria Fiatarone Singh

Authors
  1. Rhonda Orr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Fiatarone Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rhonda Orr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orr, R., Singh, M.F. The Anabolic Androgenic Steroid Oxandrolone in the Treatment of Wasting and Catabolic Disorders. Drugs 64, 725–750 (2004). https://doi.org/10.2165/00003495-200464070-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464070-00004

Keywords

Search

Navigation